Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Inhibrx Biosciences, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- −2 vs. Q4 2021
- Shares held
- 24.6M
- +1.35M (+5.8%) vs. Q4 2021
- Total value
- $548.0M
- −$467.0M (−46.0%) vs. Q4 2021
- New holders
- 16
- 40 more added
- Sold out
- 18
- 28 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 162 | $1.36B |
| Q1 2026 | 135 | $854.6M |
| Q4 2025 | 138 | $1.01B |
| Q3 2025 | 102 | $353.6M |
| Q2 2025 | 89 | $148.9M |
| Q1 2025 | 92 | $151.0M |
| Q4 2024 | 101 | $171.9M |
| Q3 2024 | 96 | $139.3M |
| Q2 2024 | 88 | $137.9M |
| Q1 2024 | 126 | $1.34B |
| Q4 2023 | 126 | $1.54B |
| Q3 2023 | 111 | $716.1M |
| Q2 2023 | 107 | $935.2M |
| Q1 2023 | 108 | $691.6M |
| Q4 2022 | 116 | $886.0M |
| Q3 2022 | 102 | $512.2M |
| Q2 2022 | 100 | $297.3M |
| Q1 2022 | 99 | $548.0M |
| Q4 2021 | 101 | $1.01B |
| Q3 2021 | 66 | $681.6M |
| Q2 2021 | 61 | $538.8M |
| Q1 2021 | 55 | $326.3M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Inhibrx Biosciences, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −61,931−100.0% | Sold out |
| EAM Global Investors LLC | 0 | $0 | 0.00% | −57,263−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −39,462−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −24,666−100.0% | Sold out |
| Gyon Technologies Capital Management, LP | 0 | $0 | 0.00% | −9,268−100.0% | Sold out |
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −8,734−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −7,220−100.0% | Sold out |
| State Board of Administration of Florida Retirement System | 0 | $0 | 0.00% | −6,268−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −5,975−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −4,748−100.0% | Sold out |
| Signet Financial Management, LLC | 0 | $0 | 0.00% | −908−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −105−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |